

# Introduction to MELODI and into the Working Group Sessions

Jacques Repussard  
Director General, IRSN, France  
Member of HLEG

# The HLEG report :

- Identifies the remaining « overarching questions » which are at the heart of uncertainties about low dose risk,
- Suggests that a multidisciplinary, integrated approach will be essential to solve these questions,
- Concludes that a EU R&T Platform would be an appropriate organisation to develop and implement this approach.

# The **M**ultidisciplinary **E**uropean **L**ow **D**ose **I**nitiative **M**E**L**O**D**I

Establish trans-national structure to:

- Develop a Strategic Research Agenda (SRA)
- Integrate national, and multilateral research programmes within the agreed SRA
- Ensure consistent SRA implementation road map, and research methodologies
- Act as a forum for interface between R&T actors and stakeholders
- Advise on investments in key infrastructures, knowledge management, and education and training

# Some Underlying Principles of MELODI


- **Open process** – mechanisms to involve any research organisation/funding body able to contribute to MELODI goals
- **Actively engage** with potential contributors from the wider scientific community, and with stakeholders
- **Step by step planned process** in the development and implementation of the scientific strategy, through the **SRA**
- **Focus initially** on developing an integrated and sustainable approach to low dose risk research

# Scientific Strategy of MELODI

## Four key elements


- Holistic approach
- Periodic review of objectives
- Dissemination of research outcomes and interaction with users
- Ensuring key pre-requisites are duly met

# MELODI: A Holistic Musical Score



# MELODI: An Orchestra for a New Symphony


→ Many Disciplines are necessary to the Low Dose Risk Research



→ Their harmony has to be organised for full efficiency, like in an orchestra. But it will take some time...

# DoReMi: The First Notes of the Symphony

→ Network of Excellence to be approved by the EC by the end 2009



→ DoReMi is designed to achieve fairly short term results in order to prove the validity of the HLEG approach, and contribute to the development of MELODI



# Respective Roles of DoReMi and MELODI


## → DoReMi, A Network of Excellence:

- To develop and implement a “transition research agenda” (TRA) within the limited time frame and organisational perimeters of the NoE
- To contribute to the wider development of MELODI, notably by bringing its scientific input into the open dialogue of the Platform
- To take into account the results of MELODI work and SRA for the future calls for R&D actions within the NoE

## → MELODI, A European Platform:

- To develop a long term strategic agenda for research and training in Europe on low dose risk issues
- The SRA and road map should be sufficiently supported by all stakeholders (including the R&D community) to allow the EC and Member States to rely on it to guide EU and national R&D policies

# How to Write the Rest of the Music Score?



# Three Chamber Orchestra to Compose the Symphony

## ***Shape of Dose-Response Curve for Cancer*** **WG 1**

Orchestra Conductor: Simon Bouffler

Music Writers: Mats Harms-Ringdhal, Harmen Bijwaard, Dominique Laurier

## ***Individual Sensitivity for Cancer*** **WG 2**

Orchestra Conductor: Mike Atkinson

Music Writers: Anna Friedl, Rafi Bentomane, Kai Rothkamm

## ***Non-Cancer Effects*** **WG 3**

Orchestra Conductor: Patrick Gourmelon

Music Writers: Paul Schofield, Colin Muirhead, Jean-René Jourdain

# General Questions and Issues To Guide the Discussion in the Working Groups (1)

- What are the areas of greatest uncertainty in low dose radiation protection research?
- Which open questions need immediate attention, and which ones can be answered later?
- In which areas is a need for further methodological development?
- In which areas is there no need for further research?

# General Questions and Issues To Guide the Discussion in the Working Groups (2)

- What are the key populations of interest (public, workers, sensitive subpopulations, etc.)?
- What are the key endpoints of interest (adverse health effects, predictive markers, etc.)?
- What kind of infrastructures are needed for further scientific research?
- How should interactions among disciplines be established to investigate low dose risk using an interdisciplinary approach?

# And now, let's start the band lyrics!

---

1<sup>st</sup> MELODI Workshop  
Stuttgart, 28-29 September 2009

